Cargando…

Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes

A previous semi‐mechanistic model described changes in fasting serum insulin (FSI), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) in patients with type 2 diabetic mellitus (T2DM) by modeling insulin sensitivity and β‐cell function. It was later suggested that change in body weight co...

Descripción completa

Detalles Bibliográficos
Autores principales: Choy, S, Kjellsson, MC, Karlsson, MO, de Winter, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728293/
https://www.ncbi.nlm.nih.gov/pubmed/26844011
http://dx.doi.org/10.1002/psp4.12051
_version_ 1782412081009524736
author Choy, S
Kjellsson, MC
Karlsson, MO
de Winter, W
author_facet Choy, S
Kjellsson, MC
Karlsson, MO
de Winter, W
author_sort Choy, S
collection PubMed
description A previous semi‐mechanistic model described changes in fasting serum insulin (FSI), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) in patients with type 2 diabetic mellitus (T2DM) by modeling insulin sensitivity and β‐cell function. It was later suggested that change in body weight could affect insulin sensitivity, which this study evaluated in a population model to describe the disease progression of T2DM. Nonlinear mixed effects modeling was performed on data from 181 obese patients with newly diagnosed T2DM managed with diet and exercise for 67 weeks. Baseline β‐cell function and insulin sensitivity were 61% and 25% of normal, respectively. Management with diet and exercise (mean change in body weight = −4.1 kg) was associated with an increase of insulin sensitivity (30.1%) at the end of the study. Changes in insulin sensitivity were associated with a decrease of FPG (range, 7.8–7.3 mmol/L) and HbA1c (6.7–6.4%). Weight change as an effector on insulin sensitivity was successfully evaluated in a semi‐mechanistic population model.
format Online
Article
Text
id pubmed-4728293
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-47282932016-02-03 Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes Choy, S Kjellsson, MC Karlsson, MO de Winter, W CPT Pharmacometrics Syst Pharmacol Original Articles A previous semi‐mechanistic model described changes in fasting serum insulin (FSI), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) in patients with type 2 diabetic mellitus (T2DM) by modeling insulin sensitivity and β‐cell function. It was later suggested that change in body weight could affect insulin sensitivity, which this study evaluated in a population model to describe the disease progression of T2DM. Nonlinear mixed effects modeling was performed on data from 181 obese patients with newly diagnosed T2DM managed with diet and exercise for 67 weeks. Baseline β‐cell function and insulin sensitivity were 61% and 25% of normal, respectively. Management with diet and exercise (mean change in body weight = −4.1 kg) was associated with an increase of insulin sensitivity (30.1%) at the end of the study. Changes in insulin sensitivity were associated with a decrease of FPG (range, 7.8–7.3 mmol/L) and HbA1c (6.7–6.4%). Weight change as an effector on insulin sensitivity was successfully evaluated in a semi‐mechanistic population model. John Wiley and Sons Inc. 2015-12-16 2016-01 /pmc/articles/PMC4728293/ /pubmed/26844011 http://dx.doi.org/10.1002/psp4.12051 Text en © 2015 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Choy, S
Kjellsson, MC
Karlsson, MO
de Winter, W
Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
title Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
title_full Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
title_fullStr Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
title_full_unstemmed Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
title_short Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
title_sort weight‐hba1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728293/
https://www.ncbi.nlm.nih.gov/pubmed/26844011
http://dx.doi.org/10.1002/psp4.12051
work_keys_str_mv AT choys weighthba1cinsulinglucosemodelfordescribingdiseaseprogressionoftype2diabetes
AT kjellssonmc weighthba1cinsulinglucosemodelfordescribingdiseaseprogressionoftype2diabetes
AT karlssonmo weighthba1cinsulinglucosemodelfordescribingdiseaseprogressionoftype2diabetes
AT dewinterw weighthba1cinsulinglucosemodelfordescribingdiseaseprogressionoftype2diabetes